Rossari Biotech Limited (ROSSARI) — Board Meeting

· NSE 🟡 Notable Neutral
📢 Key Event
Board approved Q1 FY2026 results, ESOP grant, share allotment, and Rossari International transfer.
🔮 What's Next
Completion of share transfer targeted by March 31, 2027, pending Saudi approvals.
💡 Investor Takeaway
The restructuring may streamline ownership but carries execution risk; financials remain stable with strong PAT growth.

The Board approved unaudited Q1 FY2026 results showing revenue of [amount not verified], profit after tax of [amount context mismatch] crores, and a restructuring that will transfer 100% of Rossari International to Rossari (Singapore) Pte. Ltd. The ESOP grant of 4,000 options at ₹531 each and allotment of 2,500 shares raised paid‑up capital to [amount not verified]. The sale of 9,000 RILC shares at ~₹24 crores awaits Saudi approval, with completion targeted for March 31, 2027.

📄 View Original Announcement (PDF)

About Rossari Biotech Limited (ROSSARI)

Chemicals · Chemicals & Petrochemicals · Listed on NSE

Market Cap: ₹2,806 Cr P/E: 20.6

View full ROSSARI stock details →

📡 Get AI alerts when ROSSARI files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track ROSSARI — Free

📊 More ROSSARI filings

See all ROSSARI filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

📡 Get AI alerts when ROSSARI files new disclosures

Track ROSSARI filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track ROSSARI — Free

Free account · 2 AI queries/day